<DOC>
	<DOCNO>NCT02212639</DOCNO>
	<brief_summary>Classic endemic Kaposi 's sarcoma ( KS ) lymph angio proliferation associate human herpes virus 8 ( HHV8 ) treatment poorly codify . Chemotherapies give best 30-60 % transient response . While interferon response frequent , drug often poorly tolerate elderly patient . Therefore new therapy need . Classic KS represent ideal model evaluate new drug since patient receive concomitant immunosuppressive regimen antiviral therapy . Hypoxia-inducible factor 1 ( HIF-1 alpha ) major regulator solid tumor growth therefore suitable target currently explore many cancer . Moreover HIF-1 alpha enhance HHV-8 gene expression KS induce lytic replication cycle . Digoxin anti cancer effect vivo HIF-alpha regulation several preclinical tumor model include KS . The identification HIF-1 alpha key factor HHV8 replication prompt u explore inhibition HIF-1 alpha digoxin potential therapeutic approach KS treatment consequently may regulate HHV-8 replication KS . This latter approach heighten recent data suggest Digoxin efficacy vitro others human herpes virus i.e . Herpes simplex Cytomegalovirus ( 8 ) ( 9 ) In study investigator shall evaluate benefit safety profile digoxin classic endemic KS ( serum drug concentration 0.6 1.2 ng/ml patient &lt; 75 year 0.5-0.8 ng/ml patient older 75 year The participant take study drug digoxin , total 6 cycle ( 4 weeks/cycle ) .</brief_summary>
	<brief_title>Phase II Multicentric Study Digoxin Per o Classic Endemic Kaposi ' Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Age &gt; 18 year &lt; à 80 year Classic endemic histologically confirm Kaposi 's Sarcoma ( KS ) Progressive disease KS 10 lesion involve one limb segment involvement &gt; 3 % body surface KS least 4 lesion ≥5mm Patients least 2 others cutaneous tumor available repeat pharmacodynamics evaluation At least 4 week wash KS specific therapy include chemotherapy immunotherapy Signed informed consent Symptomatic visceral lesion Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 Life expectancy ≤ 6 month Patients already receive digoxin hepatic dysfunction define serum bilirubin &gt; 25 µm/l , transaminases &gt; 3.0 time upper limit normal ( ULN ) ( 5ULN case liver metastasis ) bone marrow dysfunction define absolute neutrophil count &lt; 1500/mcl , platelet &lt; 150000/mcl hemoglobin &lt; 8g/dL renal failure creatinine clearance &lt; 40ml/mn HIV positive , active infectious hepatitis , type A , B C Uncontrolled systemic infection Pregnant lactate woman Presence follow electrocardiogram ( ECG ) : atrial arrhythmia , include atrial fibrillation flutter WolffParkinsonWhite syndrome ; auricular ventricular ( AV ) block ; heart rate &lt; 60 beats/minute &gt; 100 beats/minute ; ventricular fibrillation ; ventricular tachycardia ; premature ventricular contraction . History current cardiac arrythmia include sinus node disease , history AV Block , accessory AV pathway ( WolffParkinsonWhite Syndrome ) , history myocardial infarction , significant valvulopathy . Electrolyte imbalance ( hypokalemia , hypo hypercalcemia , hypomagnesemia ) Severe pulmonary disease hypoxia Medical condition uncontrolled hypertension , uncontrolled diabetes mellitus , hypothyroidism hyperthyroidism , would , opinion investigator , make protocol unreasonably hazardous . Major thoracic abdominal surgery within prior 3 week . GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . Immunosuppressive regimen allow include corticosteroid Use prohibit concomitant medication : calcium channel blocker diltiazem verapamil ; Class I III cardiac arrhythmic agent ( quinidine , amiodarone ) ; betablockers ( atenolol , metoprolol ) ; indomethacin ( Indocin ) ; calcium carbonate antacid ( e.g. , Maalox , Tums , Rolaids ) ; Calcium omeprazole ; antidiarrheal adsorbent ( kaolin pectin ) ; antibiotic P450 inhibitor clarithromycin , erythromycin telithromycin P450 inhibitors./such Ritonavir ) Persistent Grade &gt; 2 treatmentrelated toxicity prior therapy History digoxinrelated drug induce anaphylactic reaction Use investigational agent Patient without health insurance coverage Patient guardianship Enrollment clinical trial within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Kaposi ' sarcoma</keyword>
	<keyword>Digoxin</keyword>
</DOC>